News

Richmond-based manufacturer expands operations to reduce waste, pollution and cost in the laboratory industry

Seven years after its founding as a startup business in Richmond, Grenova Inc. has moved into a new phase of development as a company.

“We have been growing quite significantly,” said Ali Safavi, the founder and CEO of Grenova, which has a mission to reduce waste, pollution and costs in the global laboratory industry. Grenova, which stands for Green Innovation, announced plans in April to relocate its operations from a 10,000-square-foot facility in the Manchester area of South Richmond to a 35,000-square-foot building at 1900 Ellen Road just north of Scott’s Addition. The company also announced plans to invest $10.6 million to expand its production and hire 250 people over the next three years. The newly renovated facility – formerly occupied by Sampson Coatings Inc. – is now operating as Grenova’s main office, research and development and manufacturing facility, with more than 60 employees.

Grenova designs and manufactures equipment that health care businesses, universities and government agencies can install in their laboratories to wash and sterilize plastic pipette tips, the small tools used to transfer samples in medical diagnostic tests and research projects such as drug development. Grenova’s goal from the start has been to reduce the billions of pounds of plastic pipette tips that are discarded after one use and end up in landfills.

“About every two and half years, we have tripled our footprint,” said Safavi, noting that the company started in 2014 in a 3,200 square foot office in Midlothian before moving to Manchester and now to the site on Ellen Road. At the new facility, the company can make up to 2,800 cleaning and sterilization units per year, per work shift, Safavi said. That’s up from a capacity of just a few hundred units at its previous location.

To learn more please visit Richmond Times-Dispatch

Recent News

09/30/2026

Activation Capital Recognizes President Michael Rao’s 17 Years of Leadership as Authority Board Chair, Names Paul Nolde as New Chair

Activation Capital, the operating name of the Virginia Biotechnology Research Partnership Authority, today announced the election of Paul Nolde as chair of the Authority Board, succeeding Virginia Commonwealth University President Michael Rao, Ph.D., who has served as chair since 2009. Rao will remain an active member of the board, continuing his longstanding support of Activation …

09/22/2026

ATCC to Lead Lifecycle Management of Military Medical Countermeasures Under 10-Year Department of War Contract

ATCC has been awarded a 10-year Department of War (DOW) contract to coordinate lifecycle management of medical countermeasures (MCMs) developed to protect U.S. military personnel from chemical and biological threats. Under this contract, ATCC supports the mission of the Rapid Access to Products in Development (RAPID) program to enable MCM preparedness against chemical and biological …

09/22/2026

Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to QRX003 for the treatment of Peeling Skin Syndrome (PSS). QRX003 is an investigational topical serine protease inhibitor lotion. …